Literature DB >> 20109747

Defect of regulatory T cells in patients with Omenn syndrome.

Barbara Cassani1, Pietro Luigi Poliani, Daniele Moratto, Cristina Sobacchi, Veronica Marrella, Laura Imperatori, Donatella Vairo, Alessandro Plebani, Silvia Giliani, Paolo Vezzoni, Fabio Facchetti, Fulvio Porta, Luigi D Notarangelo, Anna Villa, Raffaele Badolato.   

Abstract

BACKGROUND: Omenn syndrome (OS) is an autosomal-recessive disorder characterized by severe immunodeficiency and T-cell-mediated autoimmunity. The disease is caused by hypomorphic mutations in recombination-activating genes that hamper the process of Variable (V) Diversity (D) Joining (J) recombination, leading to the generation of autoreactive T cells. We have previously shown that in OS the expression of autoimmune regulator, a key factor governing central tolerance, is markedly reduced.
OBJECTIVE: Here, we have addressed the role of peripheral tolerance in the disease pathogenesis.
METHODS: We have analyzed forkhead box protein P3 (FOXP3) expression in peripheral blood T cells of 4 patients with OS and in lymphoid organs of 8 patients with OS and have tested the suppressive activity of sorted CD4(+) CD25(high) peripheral blood T cells in 2 of these patients.
RESULTS: We have observed that CD4(+)CD25(high)T cells isolated ex vivo from patients with OS failed to suppress proliferation of autologous or allogenic CD4(+) responder T cells. Moreover, despite individual variability in the fraction of circulating FOXP3(+) CD4 cells in patients with OS, the immunohistochemical analysis of FOXP3 expression in lymph nodes and thymus of patients with OS demonstrated a severe reduction of this cell subset compared with control tissues.
CONCLUSION: Overall, these results suggest a defect of regulatory T cells in OS leading to a breakdown of peripheral tolerance, which may actively concur to the development of autoimmune manifestations in the disease. Copyright 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20109747     DOI: 10.1016/j.jaci.2009.10.023

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  38 in total

1.  Acquired Omenn-like syndrome, a novel posttransplant autoaggression syndrome reversed by rapamycin.

Authors:  Donald C Vinh; Khalid Bin Dhuban; Helen Mason; Duncan Lejtenyi; Sungmi Jung; Donald C Sheppard; Damien Faury; Nada Jabado; Ciriaco A Piccirillo
Journal:  Clin Vaccine Immunol       Date:  2011-11-16

2.  Induced pluripotent stem cells: a novel frontier in the study of human primary immunodeficiencies.

Authors:  Itai M Pessach; Jose Ordovas-Montanes; Shen-Ying Zhang; Jean-Laurent Casanova; Silvia Giliani; Andrew R Gennery; Waleed Al-Herz; Philip D Manos; Thorsten M Schlaeger; In-Hyun Park; Francesca Rucci; Suneet Agarwal; Gustavo Mostoslavsky; George Q Daley; Luigi D Notarangelo
Journal:  J Allergy Clin Immunol       Date:  2010-12-24       Impact factor: 10.793

Review 3.  Advances in basic and clinical immunology in 2010.

Authors:  Javier Chinen; William T Shearer
Journal:  J Allergy Clin Immunol       Date:  2011-02       Impact factor: 10.793

Review 4.  RAG gene defects at the verge of immunodeficiency and immune dysregulation.

Authors:  Anna Villa; Luigi D Notarangelo
Journal:  Immunol Rev       Date:  2019-01       Impact factor: 12.988

5.  Abnormalities of T-cell receptor repertoire in CD4+ regulatory and conventional T cells in patients with RAG mutations: Implications for autoimmunity.

Authors:  Jared H Rowe; Brian D Stadinski; Lauren A Henderson; Lisa Ott de Bruin; Ottavia Delmonte; Yu Nee Lee; M Teresa de la Morena; Rakesh K Goyal; Anthony Hayward; Chiung-Hui Huang; Maria Kanariou; Alejandra King; Taco W Kuijpers; Jian Yi Soh; Benedicte Neven; Jolan E Walter; Eric S Huseby; Luigi D Notarangelo
Journal:  J Allergy Clin Immunol       Date:  2017-08-31       Impact factor: 10.793

Review 6.  Genetics of allergy and allergic sensitization: common variants, rare mutations.

Authors:  Klaus Bønnelykke; Rachel Sparks; Johannes Waage; Joshua D Milner
Journal:  Curr Opin Immunol       Date:  2015-09-18       Impact factor: 7.486

7.  Omenn syndrome associated with a functional reversion due to a somatic second-site mutation in CARD11 deficiency.

Authors:  Sebastian Fuchs; Anne Rensing-Ehl; Ulrich Pannicke; Myriam R Lorenz; Paul Fisch; Yogesh Jeelall; Jan Rohr; Carsten Speckmann; Thomas Vraetz; Susan Farmand; Annette Schmitt-Graeff; Marcus Krüger; Brigitte Strahm; Philipp Henneke; Anselm Enders; Keisuke Horikawa; Christopher Goodnow; Klaus Schwarz; Stephan Ehl
Journal:  Blood       Date:  2015-08-19       Impact factor: 22.113

8.  Expansion of immunoglobulin-secreting cells and defects in B cell tolerance in Rag-dependent immunodeficiency.

Authors:  Jolan E Walter; Francesca Rucci; Laura Patrizi; Mike Recher; Stephan Regenass; Tiziana Paganini; Marton Keszei; Itai Pessach; Philipp A Lang; Pietro Luigi Poliani; Silvia Giliani; Waleed Al-Herz; Morton J Cowan; Jennifer M Puck; Jack Bleesing; Tim Niehues; Catharina Schuetz; Harry Malech; Suk See DeRavin; Fabio Facchetti; Andrew R Gennery; Emma Andersson; Naynesh R Kamani; JoAnn Sekiguchi; Hamid M Alenezi; Javier Chinen; Ghassan Dbaibo; Gehad ElGhazali; Adriano Fontana; Srdjan Pasic; Cynthia Detre; Cox Terhorst; Frederick W Alt; Luigi D Notarangelo
Journal:  J Exp Med       Date:  2010-06-14       Impact factor: 14.307

9.  Homeostatic expansion of autoreactive immunoglobulin-secreting cells in the Rag2 mouse model of Omenn syndrome.

Authors:  Barbara Cassani; Pietro Luigi Poliani; Veronica Marrella; Francesca Schena; Aisha V Sauer; Maria Ravanini; Dario Strina; Christian E Busse; Stephan Regenass; Hedda Wardemann; Alberto Martini; Fabio Facchetti; Mirjam van der Burg; Antonius G Rolink; Paolo Vezzoni; Fabio Grassi; Elisabetta Traggiai; Anna Villa
Journal:  J Exp Med       Date:  2010-06-14       Impact factor: 14.307

Review 10.  Genetics of SCID.

Authors:  Fausto Cossu
Journal:  Ital J Pediatr       Date:  2010-11-15       Impact factor: 2.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.